期刊文献+

Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy 被引量:6

Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy
下载PDF
导出
摘要 A well-known tumor suppressor, p21, acts parado-xically by promoting tumor growth in some cellular conditions. These conflicting functions have been demonstrated in association with the HBx gene and in hepatocarcinogenesis. The molecular behavior of p21 depends on its subcellular localization. Nuclear p21 may inhibit cell proliferation and be proapoptotic, while cytoplasmic p21 may have oncogenic and anti-apoptotic functions. Because most typical tumor suppressive proteins also have different effects according to subcellular localization, elucidating the regulatory mechanisms underlying nucleo-cytoplasmic transport of these proteins would be significant and may lead to a new strategy for anti-hepatocellular carcinoma(HCC) therapy. Chromosome region maintenance 1(CRM1) is a major nuclear export receptor involved in transport of tumor suppressors from nucleus to cytoplasm. Expression of CRM1 is enhanced in a variety of malignancies and in vitro studies have shown the efficacy of specific inhibition of CRM1 against cancer cell lines. Interestingly, interferon may keep p21 in the nucleus; this is one of the mechanisms of its anti-hepatocarcinogenic function. Here we review the oncogenic property of p21, which depends on its subcellular localization, and discuss the rationale underlying a new strategy for HCC treatment and prevention. A well-known tumor suppressor, p21, acts parado-xically by promoting tumor growth in some cellular conditions. These conflicting functions have been demonstrated in association with the HBx gene and in hepatocarcinogenesis. The molecular behavior of p21 depends on its subcellular localization. Nuclear p21 may inhibit cell proliferation and be proapoptotic, while cytoplasmic p21 may have oncogenic and anti-apoptotic functions. Because most typical tumor suppressive proteins also have different effects according to subcellular localization, elucidating the regulatory mechanisms underlying nucleo-cytoplasmic transport of these proteins would be significant and may lead to a new strategy for anti-hepatocellular carcinoma(HCC) therapy. Chromosome region maintenance 1(CRM1) is a major nuclear export receptor involved in transport of tumor suppressors from nucleus to cytoplasm. Expression of CRM1 is enhanced in a variety of malignancies and in vitro studies have shown the efficacy of specific inhibition of CRM1 against cancer cell lines. Interestingly, interferon may keep p21 in the nucleus; this is one of the mechanisms of its anti-hepatocarcinogenic function. Here we review the oncogenic property of p21, which depends on its subcellular localization, and discuss the rationale underlying a new strategy for HCC treatment and prevention.
出处 《World Journal of Gastroenterology》 SCIE CAS 2015年第42期12150-12156,共7页 世界胃肠病学杂志(英文版)
基金 Supported by Grant-in-Aid for Scientific Research(C)(22590722 for Ohkoshi S)from the Japan Society for the promotion of Science(JSPS)
关键词 P21 Tumor SUPPRESSORS ONCOGENE SUBCELLULAR localiz p21 Tumor suppressors Oncogene Subcellular localiz
  • 相关文献

参考文献20

  • 1Yefei Huang,Weimin Wang,Yansu Chen,Yulin Huang,Jianbing Zhang,Song He,Yongfei Tan,Fulin Qiang,Aiping Li,Oluf Dimitri R?e,Shouyu Wang,Yan Zhou,Jianwei Zhou.The opposite prognostic significance of nuclear and cytoplasmic p21 expression in resectable gastric cancer patients[J]. Journal of Gastroenterology . 2014 (11)
  • 2Thomas Monecke,Achim Dickmanns,Ralf Ficner.Allosteric control of the exportin CRM 1 unraveled by crystal structure analysis[J]. FEBS J . 2014 (18)
  • 3Yun Zheng,Sigal Gery,Haibo Sun,Sharon Shacham,Michael Kauffman,H. Phillip Koeffler.KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma[J]. Cancer Chemotherapy and Pharmacology . 2014 (3)
  • 4Fang Zhou,Wensheng Qiu,Ruyong Yao,Jinyu Xiang,Xiaoxiao Sun,Shihai Liu,Jing Lv,Lu Yue.CRM1 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas[J]. Medical Oncology . 2013 (4)
  • 5Masahiko Yano,Shogo Ohkoshi,Yo‐hei Aoki,Hiromichi Takahashi,Sou Kurita,Kazuhide Yamazaki,Kenta Suzuki,Satoshi Yamagiwa,Ayumi Sanpei,Shun Fujimaki,Toshifumi Wakai,Shin‐ei Kudo,Yasunobu Matsuda,Yutaka Aoyagi.Hepatitis B virus X induces cell proliferation in the hepatocarcinogenesis via up‐regulation of cytoplasmic p21 expression[J]. Liver Int . 2013 (8)
  • 6Parvathi Ranganathan,Xueyan Yu,Caroline Na,Ramasamy Santhanam,Sharon Shacham,Michael Kauffman,Alison Walker,Rebecca Klisovic,William Blum,Michael Caligiuri,Carlo M. Croce,Guido Marcucci,Ramiro Garzon.Preclinical activity of a novel CRM1 inhibitor in acute myeloid leukemia[J]. Blood . 2012 (9)
  • 7Alejandro Forner,Josep M Llovet,Jordi Bruix.Hepatocellular carcinoma[J]. The Lancet . 2012 (9822)
  • 8Joel G. Turner,Jana Dawson,Daniel M. Sullivan.Nuclear export of proteins and drug resistance in cancer[J]. Biochemical Pharmacology . 2011 (8)
  • 9Hashem B. El-Serag.Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma[J]. Gastroenterology . 2012 (6)
  • 10Yuehua Huang,Shuping Tong,Andrew W. Tai,Munira Hussain,Anna S.F. Lok.Hepatitis B Virus Core Promoter Mutations Contribute to Hepatocarcinogenesis by Deregulating SKP2 and Its Target, p21[J].Gastroenterology.2011(4)

共引文献37

同被引文献11

引证文献6

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部